Nordicus Partners Corporation (NORD)
| Market Cap | 95.51M +2.8% |
| Revenue (ttm) | n/a |
| Net Income | -5.07M |
| EPS | -0.27 |
| Shares Out | 19.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,634 |
| Open | 4.750 |
| Previous Close | 5.090 |
| Day's Range | 3.610 - 4.912 |
| 52-Week Range | 1.480 - 5.150 |
| Beta | -0.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 25, 2017 |
About NORD
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Financial Performance
Financial StatementsNews
Nordicus Partners Corporation Announces Uplisting to The Nasdaq Capital Market
BEVERLY HILLS, California, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a biotech company specializing in developing breakthrough therap...
Nordicus Partners Corporation Appoints Elizabeth Addonizio to Its Board of Directors
Appointment strengthens board independence and financial expertise as Company advances its clinical pipeline. BEVERLY HILLS, California, Sept.
Nordicus Partners Corporation Corporate Update
BEVERLY HILLS, California, June 15, 2026 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a biotech company specializing in developing breakthrough therap...
NoviThera has initiated the first efficacy animal studies
BEVERLY HILLS, California, Nov. 13, 2025 (GLOBE NEWSWIRE) -- NoviThera ApS (“NoviThera”), a majority owned subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a fi...
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.
BEVERLY HILLS, California, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consultin...
Orocidin develops novel cGMP manufacturing process in collaboration with Syngene
The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use BEVERLY HILLS, California, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...
Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS
BEVERLY HILLS, California, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic...
Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market
BEVERLY HILLS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. l...
Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors
Beverly Hills, California, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a business accelerator and holding company specializing in provi...
Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia
BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial co...
Orocidin's QR-01 Shows Positive Results in Treating Periodontitis in Dogs
BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulti...
Orocidin and Syngene Partner to Accelerate Biotech Innovation
BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consultin...
Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consultin...
Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia
BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial con...
Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment
BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company spe...
Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin's Breakthrough Treatment for Periodontitis
BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic...
Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
BEVERLY HILLS, California, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic a...
NORDICUS now trading under symbol NORD
BEVERLY HILLS, California, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic a...
Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S
Beverly Hills, California., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Nordicus Partners Corporation Acquires Bio-Convert ApS
Beverly Hills, California., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Nordicus Partners Corporation Announces Reverse Stock Split
Beverly Hills, California., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Nordicus Partners To Host Investor Relations Webinar on July 10, 2024
Beverly Hills, California., July 03, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In Denmark
Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Orocidin – New Insights Into The Treatment Of Periodontitis
Beverly Hills, California., June 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors
Beverly Hills, California, June 04, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic ...